Related Experiment Video

Updated: Oct 6, 2026

In situ Subcellular Fractionation of Adherent and Non-adherent Mammalian Cells
09:20

In situ Subcellular Fractionation of Adherent and Non-adherent Mammalian Cells

Published on: July 23, 2010

The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the

E W Wu1, K E Clemens, D V Heck

  • 1Laboratory of Tumor Virus Biology, National Cancer Institute, Bethesda, Maryland 20892.

Journal of Virology
|April 1, 1993
PubMed

Insights

High-risk human papillomavirus E7 oncoproteins disrupt retinoblastoma protein (pRB)/transcription factor E2F complexes, with binding efficiency correlating to E7

Area of Science:

  • Molecular Biology
  • Virology
  • Cancer Research

Background:

  • The retinoblastoma tumor suppressor protein (pRB) forms complexes with the cellular transcription factor E2F, regulating cell cycle progression.
  • Human papillomaviruses (HPVs) encode E7 oncoproteins that interfere with pRB function, contributing to oncogenesis.
  • Differences in HPV risk (high-risk vs. low-risk) are associated with variations in E7 oncoprotein activity.

Purpose of the Study:

  • To investigate how high-risk and low-risk HPV E7 oncoproteins disrupt the pRB/E2F complex.
  • To determine the role of pRB binding efficiency and specific E7 protein regions in this disruption process.

Main Methods:

  • Biochemical assays to study the interaction between HPV E7 oncoproteins and the pRB/E2F complex.
  • Analysis of E7 protein variants with mutations in the pRB binding site and adjacent phosphorylation sites.
  • Use of E7-derived peptides to assess the necessity of specific protein domains.

Main Results:

  • The efficiency of E7 oncoprotein binding to pRB directly correlated with its ability to disrupt the pRB/E2F complex.
  • The pRB binding site within E7 was identified as the primary determinant for these observed differences between high-risk and low-risk HPV E7.
  • Phosphorylation status of a nearby casein kinase II site in E7 did not significantly affect pRB/E2F complex disruption.
  • E7 peptides containing only the pRB binding site were insufficient to disrupt the pRB/E2F complex, indicating the requirement for additional E7 sequences.

Conclusions:

  • Disruption of the pRB/E2F complex by HPV E7 oncoproteins is dependent on both the pRB binding efficiency and additional carboxy-terminal sequences of E7.
  • These findings suggest that E7 may interact with pRB at sites distinct from those bound by E2F.
  • Understanding these molecular interactions is crucial for comprehending HPV-mediated oncogenesis.

More Related Videos

Analysis of Cell Cycle Position in Mammalian Cells12:19

Analysis of Cell Cycle Position in Mammalian Cells

Published on: January 21, 2012

Inducible and Reversible Dominant-negative (DN) Protein Inhibition08:35

Inducible and Reversible Dominant-negative (DN) Protein Inhibition

Published on: January 7, 2019

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...